OPT Opthea

Opthea to Present at the OIS Retina Innovation Summit at ARVO

Opthea to Present at the OIS Retina Innovation Summit at ARVO

MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company’s clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina Innovation Summit prior to the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4, 2024 in Seattle, Washington.

OIS Retina Innovation Summit Details

SessionInnovation Showcase
Date:Saturday, May 4, 2024
Time:8:35 to 9:50 a.m. PDT
Presenter:Frederic Guerard, PharmD, CEO



About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn. 

Authorized for release to ASX by Frederic Guerard, CEO 

Investor Inquiries

PJ Kelleher 

LifeSci Advisors, LLC 

Email:

Phone: 617-430-7579 

Media Inquiries 

Silvana Guerci-Lena 

NorthStream Global Partners 

 

Join our email database to receive program updates:  

Tel: +61 (0) 3 9826 0399, Email: Web:    



EN
25/04/2024

Underlying

OPTOpthea

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Opthea

 PRESS RELEASE
Free
OPT OPTHEA

Opthea Provides Corporate Update

Opthea Provides Corporate Update Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st MELBOURNE, Australia and PRINCETON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), today provided a corporate update following the successful settlement of the Development Funding Agreement ("DFA") with the two investors under ...

August 18, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Announces Decision to Discontinue Wet AMD Trials

Opthea Announces Decision to Discontinue Wet AMD Trials ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing...

March 31, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Announces COAST Phase 3 Trial Topline Results

Opthea Announces COAST Phase 3 Trial Topline Results COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular de...

March 24, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Announces Phase 2b Wet AMD Publication

Opthea Announces Phase 2b Wet AMD Publication Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the publication of sozinibercept Phase 2b...

March 3, 2025 1 EN
 PRESS RELEASE
Free
OPT OPTHEA

Opthea Reports Half Year Results and Business Updates

Opthea Reports Half Year Results and Business Updates Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (mid-CY25) MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the six m...

February 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch